drugset

drugset / Trial / NCT04385056

Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of Bradykinesia

NCT04385056 ↗

Phase 1 Unknown 15 enrolled IMAC Holdings, Inc.

RandomizedSingle-groupOpen-labelTreatment

Summary

Investigate the safety and tolerability of umbilical cord-derived allogeneic mesenchymal stem cells to treat patients with Bradykinesia.

Timeline

Start: 2020-12-15
Primary completion: 2022-07-01
Completion: 2022-07-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MSCTC-0010	Cell therapy	—	Other

Indications